日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

索他西普治疗骨髓纤维化贫血:一项研究者发起的II期研究

Bose, Prithviraj; Masarova, Lucia; Pemmaraju, Naveen; Bledsoe, Sharon D; Daver, Naval G; Jabbour, Elias J; Kadia, Tapan M; Estrov, Zeev; Kornblau, Steven M; Andreeff, Michael; Jain, Nitin; Cortes, Jorge E; Borthakur, Gautam; Alvarado, Yesid; Richie, Mary Ann; Dobbins, Mackenzie H; McCrackin, Selene A; Zhou, Lingsha; Pierce, Sherry A; Wang, Xuemei; Pike, Allison M; Garcia-Manero, Guillermo; Kantarjian, Hagop M; Verstovsek, Srdan

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

表观遗传复合物抑制靶向TP53突变型急性髓系白血病(AML)和AML干细胞/祖细胞

Carter, Bing Z; Mak, Po Yee; Muftuoglu, Muharrem; Tao, Wenjing; Ke, Baozhen; Pei, Jingqi; Bedoy, Andrea D; Ostermann, Lauren B; Nishida, Yuki; Isgandarova, Sevinj; Sobieski, Mary; Nguyen, Nghi; Powell, Reid T; Martinez-Moczygemba, Margarita; Stephan, Clifford; Basyal, Mahesh; Pemmaraju, Naveen; Boettcher, Steffen; Ebert, Benjamin L; Shpall, Elizabeth J; Wallner, Barbara; Morgan, Robert A; Karras, Georgios I; Moll, Ute M; Andreeff, Michael

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

米拉地美坦 (DS3032b) 联合低剂量阿糖胞苷(加或不加维奈托克)治疗急性髓系白血病的 I 期研究:临床安全性、有效性和相关性分析

Senapati, Jayastu; Muftuoglu, Muharrem; Ishizawa, Jo; Abbas, Hussein A; Loghavi, Sanam; Borthakur, Gautam; Yilmaz, Musa; Issa, Ghayas C; Dara, Samuel I; Basyal, Mahesh; Li, Li; Naqvi, Kiran; Pourebrahim, Rasoul; Jabbour, Elias J; Kornblau, Steven M; Short, Nicholas J; Pemmaraju, Naveen; Garcia-Manero, Guillermo; Ravandi, Farhad; Khoury, Joseph; Daver, Naval; Kantarjian, Hagop M; Andreeff, Michael; DiNardo, Courtney D

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality

维奈托克联合地西他滨与强化化疗治疗急性髓系白血病:一项按治疗相关死亡风险分层的倾向评分匹配分析

Maiti, Abhishek; Qiao, Wei; Sasaki, Koji; Ravandi, Farhad; Kadia, Tapan M; Jabbour, Elias J; Daver, Naval G; Borthakur, Gautam; Garcia-Manero, Guillermo; Pierce, Sherry A; Montalbano, Kathryn S; Pemmaraju, Naveen; Naqvi, Kiran; Ohanian, Maro; Short, Nicholas J; Alvarado, Yesid; Takahashi, Koichi; Yilmaz, Musa; Jain, Nitin; Kornblau, Steven M; Andreeff, Michael; Bose, Prithviraj; Ferrajoli, Alessandra; Issa, Ghayas C; Masarova, Lucia; Thompson, Philip A; Rausch, Caitlin R; Ning, Jing; Kantarjian, Hagop M; DiNardo, Courtney D; Konopleva, Marina Y

Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis

成骨微环境在正常造血和白血病发生调控中的作用

Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells

新型 BMI-1 抑制剂 PTC596 可下调 MCL-1 并诱导急性髓系白血病祖细胞中 p53 独立的线粒体凋亡

Y Nishida, A Maeda, M J Kim, L Cao, Y Kubota, J Ishizawa, A AlRawi, Y Kato, A Iwama, M Fujisawa, K Matsue, M Weetall, M Dumble, M Andreeff, T W Davis, A Branstrom, S Kimura, K Kojima

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo

β-catenin 和 Bcr-Abl 的联合抑制可协同靶向体外和体内对酪氨酸激酶抑制剂耐药的急变期慢性粒细胞白血病原始细胞和祖细胞。

H Zhou ,P Y Mak ,H Mu ,D H Mak ,Z Zeng ,J Cortes ,Q Liu ,M Andreeff ,B Z Carter

GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer

GD3 合酶调节乳腺癌上皮-间质转化和转移

T R Sarkar, V L Battula, S J Werden, G V Vijay, E Q Ramirez-Peña, J H Taube, J T Chang, N Miura, W Porter, N Sphyris, M Andreeff, S A Mani

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

SNDX-275(恩替诺司他)通过抑制组蛋白去乙酰化酶(HDAC)来恢复白血病相关转录因子Nur77和Nor1以及急性髓系白血病(AML)中关键促凋亡蛋白的表达。

Zhou, L; Ruvolo, V R; McQueen, T; Chen, W; Samudio, I J; Conneely, O; Konopleva, M; Andreeff, M

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors

凋亡信号的激活会消除慢性粒细胞白血病 (CML) 中的 CD34+ 祖细胞,且与酪氨酸激酶抑制剂的反应无关

D H Mak, R-Y Wang, W D Schober, M Konopleva, J Cortes, H Kantarjian, M Andreeff, B Z Carter